Genmab — Oktober 2019
-
Det bliver til jul.
-
I wonder if they are considering a limitation of the indication. We have this problem with Cassiopeia as well as Griffin, that high risk pts don't really benefit from adding dara. In Cassiopeia they do benefit a little, but that is because VTd is a "weaker" combination. In Griffin HR-pts don't benefit at all, as VRd is a better combination. So for 15% of pts it would be waste of money to add dara.
-
i was thinking if there were enough patients in that subgroup HR to make that conclusion, but there are i think, just checked https://multiplemyelomahub.com/medical-information/imw-2019-subgroup-analysis-cassiopeia
-
the press release from Janssen https://www.businesswire.com/news/home/20191018005289/en/CHMP-Grants-Positive-Opinion-Expanded-Janssen’s-Darzalex
▼ -
And in Griffin as well: Dr. Voorhees noted that D-RVd was favored across all subgroups for MRD negativity and stringent compete response, except among patients with high-risk cytogenetics and stage III disease. https://www.mdedge.com/hematology-oncology/article/208465/multiple-myeloma/combo-could-be-new-standard-transplant-eligible
-
De dårlige nyheder bliver ved med at vælte ned over JJ.
-
-
1.409,50.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind